Potassium citrate

Description

Potassium Citrate is a citrate salt of potassium with the empirical formula K3C6H5O7 • H2O. It is presented as yellowish to tan, oral wax-matrix tablets. Each tablet contains 5 mEq (540 mg), 10 mEq (1080 mg), or 15 mEq (1620 mg) of potassium citrate. Inactive ingredients include carnauba wax and magnesium stearate.

Uses and Indications

Potassium Citrate is indicated for the management of renal tubular acidosis (RTA) associated with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, and uric acid lithiasis, with or without the presence of calcium stones.

There are no teratogenic or nonteratogenic effects associated with the use of Potassium Citrate.

Dosage and Administration

For patients with severe hypocitraturia (urinary citrate < 150 mg/day), therapy should be initiated at a dosage of 60 mEq per day. This can be administered as 30 mEq two times per day or 20 mEq three times per day. Doses should be taken with meals, within 30 minutes after meals, or at a bedtime snack to enhance absorption and efficacy.

In cases of mild to moderate hypocitraturia (urinary citrate > 150 mg/day), therapy should commence at a dosage of 30 mEq per day. This can be given as 15 mEq two times per day or 10 mEq three times per day, also with meals, within 30 minutes after meals, or at a bedtime snack.

It is essential to adhere to these dosing schedules to optimize therapeutic outcomes and minimize potential side effects.

Contraindications

Use of this product is contraindicated in the following situations:

Patients with hyperkalemia or conditions predisposing to hyperkalemia, including chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, and extensive tissue breakdown, due to the risk of exacerbating elevated potassium levels.

Patients with gastrointestinal conditions that may cause arrest or delay in tablet passage, such as delayed gastric emptying, esophageal compression, intestinal obstruction, or stricture, as these conditions may hinder proper absorption.

Patients with peptic ulcer disease, as the product may exacerbate gastrointestinal irritation.

Patients with active urinary tract infections, due to the potential for worsening the infection or complicating treatment.

Patients with renal insufficiency, specifically those with a glomerular filtration rate of less than 0.7 ml/kg/min, as this may lead to accumulation of the product and increased risk of adverse effects.

Warnings and Precautions

Patients receiving Potassium Citrate should be closely monitored for the development of hyperkalemia, particularly in those with compromised renal function or conditions that impair potassium excretion, such as severe myocardial damage or heart failure. Hyperkalemia can lead to serious complications, including cardiac arrest, and may progress rapidly without warning signs. Therefore, the use of Potassium Citrate in patients with chronic renal failure or similar conditions is contraindicated.

In addition, healthcare professionals should remain vigilant for gastrointestinal complications. If patients experience severe vomiting, abdominal pain, or gastrointestinal bleeding, Potassium Citrate must be discontinued immediately. In such cases, further evaluation is warranted to rule out serious conditions such as bowel perforation or obstruction.

It is imperative that healthcare providers educate patients on the importance of reporting any adverse symptoms promptly to ensure timely intervention and management.

Side Effects

Patients may experience a range of adverse reactions associated with Potassium Citrate administration. Common adverse reactions include minor gastrointestinal complaints such as abdominal discomfort, vomiting, diarrhea, loose bowel movements, and nausea.

Serious adverse reactions have been reported, including hyperkalemia, particularly in patients with impaired mechanisms for excreting potassium. This condition can lead to cardiac arrest and may develop rapidly, often without symptoms. In cases of severe vomiting, abdominal pain, or gastrointestinal bleeding, Potassium Citrate should be discontinued immediately, and the possibility of bowel perforation or obstruction should be investigated.

Additional considerations include patients with pre-existing hyperkalemia or conditions that predispose them to hyperkalemia, such as chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, and extensive tissue breakdown. Caution is also advised for patients who may experience delays in tablet passage through the gastrointestinal tract, including those with delayed gastric emptying, esophageal compression, intestinal obstruction, or stricture. Furthermore, patients with peptic ulcer disease, active urinary tract infections, or renal insufficiency (with a glomerular filtration rate of less than 0.7 ml/kg/min) should be closely monitored.

Drug Interactions

Concomitant administration of potassium-sparing diuretics is contraindicated, as the simultaneous use of these agents can lead to severe hyperkalemia.

Pharmacodynamic interactions may occur with drugs that slow gastrointestinal transit time, such as anticholinergics. These agents can exacerbate gastrointestinal irritation associated with potassium salts, necessitating caution when co-administered.

For patients receiving renin-angiotensin-aldosterone inhibitors, it is advisable to monitor serum potassium levels closely due to the risk of hyperkalemia.

Nonsteroidal anti-inflammatory drugs (NSAIDs) may also increase the risk of hyperkalemia; therefore, monitoring of potassium levels is recommended when these medications are used concurrently.

Packaging & NDC

The table below lists all NDC Code configurations of Potassium Citrate, the U.S. brand-name prescription product. Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established. Therefore, the use of this medication in children is not recommended until further data is available to support its use in this population.

Geriatric Use

Elderly patients may not have specific information available regarding the use of this medication, including dosage adjustments or safety concerns. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to closely monitor these patients for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

The safety of Potassium Citrate during pregnancy has not been established, as animal reproduction studies have not been conducted. There is insufficient data to determine whether Potassium Citrate can cause fetal harm or affect reproductive capacity in humans. Therefore, Potassium Citrate should be administered to pregnant patients only if the potential benefits justify the potential risks to the fetus. Given its classification as Pregnancy Category C, healthcare professionals are advised to exercise caution and consider alternative treatments when appropriate.

Lactation

The normal potassium ion content of human milk is approximately 13 mEq/L. It is currently unknown whether Potassium Citrate affects this potassium content in breast milk. Therefore, Potassium Citrate should be administered to lactating mothers only if clearly needed, taking into consideration the potential implications for breastfed infants.

Renal Impairment

Patients with renal impairment may experience significant risks associated with the administration of Potassium Citrate. In individuals with compromised mechanisms for potassium excretion, the use of Potassium Citrate can lead to hyperkalemia, which may progress to cardiac arrest. This potentially fatal condition can develop rapidly and may be asymptomatic. Therefore, the use of Potassium Citrate is contraindicated in patients with chronic renal failure or any other conditions that impair potassium excretion, such as severe myocardial damage or heart failure. Careful consideration and monitoring are essential when treating patients with reduced kidney function to prevent serious adverse effects.

Hepatic Impairment

There is no information available regarding the use of this medication in patients with hepatic impairment. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions specified for individuals with compromised liver function. Healthcare professionals should exercise caution and consider the lack of data when prescribing this medication to patients with liver problems.

Overdosage

In cases of overdosage, hyperkalemia may develop rapidly, particularly in patients with compromised mechanisms for potassium excretion. This condition can be asymptomatic initially but poses a significant risk of cardiac arrest if not addressed promptly.

Management of Hyperkalemia

The management of hyperkalemia involves several critical steps. Close monitoring for arrhythmias and electrolyte changes is essential. Immediate elimination of any medications containing potassium, as well as potassium-sparing agents, is crucial to mitigate further increases in serum potassium levels. Additionally, dietary modifications should be implemented, which include the removal of potassium-rich foods such as almonds, apricots, bananas, and spinach.

In cases where the patient is at low risk for digitalis toxicity, intravenous calcium gluconate may be administered to stabilize cardiac membranes. For the reduction of serum potassium levels, it is recommended to administer a 10% dextrose solution at a rate of 300-500 mL/hr, combined with 10-20 units of crystalline insulin per 1,000 mL. Furthermore, correction of acidosis with intravenous sodium bicarbonate is an integral part of the treatment protocol for hyperkalemia.

In severe instances of hyperkalemia, more invasive interventions such as hemodialysis or peritoneal dialysis may be required to effectively lower potassium levels. It is important to note that in patients receiving digitalis, care must be taken to avoid lowering potassium levels too rapidly, as this can precipitate digitalis toxicity.

Nonclinical Toxicology

Animal reproduction studies have not been conducted to evaluate the potential teratogenic effects of Potassium Citrate. Consequently, it remains unknown whether Potassium Citrate can cause fetal harm when administered to a pregnant woman or if it can affect reproductive capacity. Therefore, Potassium Citrate should be administered to a pregnant woman only if clearly needed.

Regarding non-teratogenic effects, the normal potassium ion content of human milk is approximately 13 mEq/L. It is not established whether Potassium Citrate influences this potassium content. As such, Potassium Citrate should be given to a breastfeeding woman only if clearly needed.

No specific details regarding nonclinical toxicology or animal pharmacology and toxicology are provided in the available insert.

Postmarketing Experience

No postmarketing experience details are available in the provided text.

Patient Counseling

Advise patients to take each dose of the medication without crushing, chewing, or sucking the tablet to ensure proper absorption and effectiveness. It is important to instruct patients to take this medicine only as directed, particularly if they are also using diuretics and digitalis preparations, as this can affect their treatment regimen.

Patients should be informed to consult their doctor if they experience any difficulty swallowing the tablets or if they feel that the tablet is sticking in their throat. Additionally, they must be made aware that they should seek immediate medical attention if they notice tarry stools or any other signs of gastrointestinal bleeding, as these may indicate serious side effects.

Finally, remind patients that their doctor will conduct regular blood tests and electrocardiograms to monitor their safety while on this medication. This ongoing assessment is crucial for ensuring the patient's well-being during treatment.

Storage and Handling

The product is supplied in a tight container to ensure its integrity and stability. It is essential to maintain proper storage conditions to preserve the quality of the product.

Additional Clinical Information

Clinicians should closely monitor patients for signs of hyperkalemia through periodic blood tests and ECGs. The postmarketing experience indicates that the frequency of gastrointestinal lesions associated with wax-matrix potassium chloride products is estimated at one per 100,000 patient-years. Although experience with Potassium Citrate is limited, a similar frequency of gastrointestinal lesions is anticipated.

FDA Insert (PDF)

This document is the official FDA-approved prescribing information for Potassium Citrate as submitted by Biocomp Pharma, Inc.. It includes detailed information about indications, dosage, contraindications, warnings, and clinical pharmacology.

View full prescribing information (PDF)